Table 2.
Risk scores for hepatocellular carcinoma development in patients with chronic hepatitis B
| Age (years) | Sex | Albumin (g/L) | Bilirubin (μmol/L) | ALT (IU/L) | HBeAg | HBV DNA (copies/mL) | Cirrhosis | Platelets (/mm3) | |
|---|---|---|---|---|---|---|---|---|---|
| GAG-HCC [39] | In years | M: 16 | N.A. | N.A. | N.A. | N.A. | 3 x log | Yes: 33 | N.A. |
| F: 0 | No: 0 | ||||||||
| CU-HCC [40] | ≤50: 0 | N.A. | ≤35: 20 | ≤18: 1.5 | N.A. | N.A. | <4 log: 0 | Yes: 15 | N.A. |
| >50: 3 | <35: 0 | >18: 1.5 | 4-6 log: 1 | No: 0 | |||||
| >6 log: 4 | |||||||||
| REACH-B [41] | 30-34: 0 | M: 2 | N.A. | N.A. | <15: 0 | +: 2 | <4 log: 0 | N.A. | N.A. |
| 35-39: 1 | F: 0 | 15-44: 1 | -: 0 | 4-5 log: 3 | |||||
| 40-44: 2 | ≥45: 2 | 5-6 log: 5 | |||||||
| 45-49: 3 | ≥6 log: 4 | ||||||||
| 50-54: 4 | |||||||||
| 55-59: 5 | |||||||||
| 60-65: 6 | |||||||||
| PAGE-B [42] | 16-29: 0 | F: 0 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | ≥200,000: 0 |
| 30-39: 2 | M: 6 | 100,000-199,999: 6 | |||||||
| 40-49: 4 | <100,000: 9 | ||||||||
| 50-59: 6 | |||||||||
| 60-69: 8 | |||||||||
| ≥70: 10 |
N.A., not applicable; M, male; F, female.